Two Plasma Donor Deaths at Private Canadian Clinics Under Federal Investigation
Two individuals have died in Canada after donating plasma at a chain of private clinics currently under federal investigation for significant operational deficiencies. The deaths occurred at facilities operated by the Spanish healthcare company Grifols, sparking concerns over safety protocols and regulatory oversight in the country's plasma collection system.
Details of the Fatal Incidents
Health Canada, the federal regulatory agency, reported receiving notifications of "fatal adverse reactions" following plasma donations in October 2025 and January 2026. The first victim was identified by friends as Rodiyat Alabede, a 22-year-old international student who donated plasma in Winnipeg on October 25. Alabede, described as a compassionate aspiring social worker, tragically passed away shortly after her donation.
Three months later, another donor died at a different Winnipeg location operated by Grifols. In both cases, donors experienced distress during the donation process, according to sources familiar with the incidents.
Company Response and Regulatory Findings
Grifols stated it has "no reason to believe that there is a correlation between the donors' passing and plasma donation," emphasizing that all donors undergo extensive health evaluations before being deemed eligible. However, federal inspection reports reveal troubling patterns at multiple Grifols facilities.
Recent inspections at clinics in Saskatchewan and Alberta identified numerous deficiencies, including failures to accurately assess donor suitability, inadequate equipment maintenance, and incomplete record-keeping. One Saskatchewan facility received a non-compliant rating with 11 documented violations of Canada's Food and Drugs Act and blood regulations.
Broader Safety Concerns and Historical Context
The deaths occur against the backdrop of Canada's tainted blood scandal of the 1980s and early 1990s, when thousands were infected with HIV/AIDS and hepatitis C through contaminated blood products. Curtis Brandell, a blood safety activist, expressed alarm at the recent fatalities, noting that when he learned of the second death in Winnipeg, "alarm bells started going off."
Brandell, whose uncles were infected during the earlier scandal, warned that current issues with record-keeping and equipment cleanliness echo past failures. "We were promised transparency. That's not what we're getting," he stated, criticizing the increasing role of private companies in Canada's blood plasma collection system.
Systemic Issues and Compensation Practices
Canada faces ongoing challenges with plasma self-sufficiency, relying heavily on imports from the United States. Grifols has become a major supplier of immunoglobulin, a plasma-derived medication, while operating 17 facilities across the country. The company compensates donors up to C$100 per donation, with frequent donors eligible for additional bonuses through a "super hero rewards" program.
Only three provinces—Ontario, British Columbia, and Quebec—maintain bans on paid plasma donations, but Grifols has found ways to operate within these jurisdictions through agreements with Canadian Blood Services.
Ongoing Investigations and Legal Proceedings
Health Canada continues to investigate both fatalities, conducting immediate site visits after each incident. Meanwhile, one Winnipeg Grifols facility faces a lawsuit from donor Craig Loney, who claims a faulty plasma separation machine caused permanent kidney damage. Grifols has moved to dismiss the case, arguing donors are informed of procedural risks.
The Canadian Blood Services expressed deep sadness over the deaths while maintaining it follows "the highest safety standards." Provincial health agencies were only recently notified about the fatalities, despite the first occurring nearly six months ago.
As federal inspectors continue their work, questions remain about whether Canada's plasma collection system maintains adequate safeguards to prevent further tragedies in a sector still haunted by historical failures.
